Is cancer care too expensive for poor countries?

Tom Paulson

No doctor, no medicine at clinic in rural Nigeria

There’s a big push going on right now to expand the scope of the global health agenda, to include many non-communicable diseases (NCDs) like cancer.

The American Society of Clinical Oncology (cancer docs) this week called upon President Barack Obama to push the United Nations to add cancer to the list of priority diseases in global health. The UN, which is holding a special high-level meeting on NCDs in September, seems likely to do so. The UN’s World Health Organization already resolved to do this last year.

Preventing cancer should definitely be on the agenda, as much of that is a matter of behavior change. But should cancer treatment be on the agenda?

My KPLU colleague Keith Seinfeld covered a March conference that addressed this question in his report Cancer joins AIDS, malaria as global health issue.

Keith quoted one Seattle doc claiming that treatment for breast cancer is cheap enough to be feasible in poor countries. But as NPR’s Scott Hensley recently noted, Even Many Americans Can’t Afford Cancer Care.

The AP reports that even up-and-coming countries like India already are being overwhelmed by health costs.

I’ve written about this issue before — mostly from the perspective of those who are advocating to get their cause on the global health agenda, whether it is cancer or mental illness or some other “neglected disease.” I missed another discussion about cancer in the global context yesterday, put on in Seattle by the World Affairs Council and featuring some leading cancer experts advocating, of course, for their area of expertise.

Maybe some of those who attended the WAC event will have something to add here.

The big question that often seems to go unanswered or glossed over is this:

Given that the international community is already having trouble meeting the demand for simpler and cheaper health interventions (children’s vaccines, basic antibiotics, malaria drugs) is much of cancer care too expensive for the global health agenda?

On the battlefield, medics developed the concept of triage — of deciding who to try to save and who to let die. It’s a brutal calculus, but one we make every day in global health by virtue of what gets funded and what doesn’t. Does global health, which was once a neglected field but now seems to be everybody’s best friend, need triage?

Jake Marcus, a fellow at the UW Institute for Health Metrics and Evaluation, recently wrote this article for The Atlantic expressing his doubts about whether the NCD movement in general will be able to gain much momentum.

Perhaps someone should be raising more doubts about the converse, about the risk of actually making the global health agenda too inclusive. Cancer docs want to fight cancer and they want to help even the poorest people. That’s great and some forms of cancer care will be applicable in low-resource communities.

But without some kind of prioritized global health strategy — some kind of triage that takes cost, poor country resources and complexity into account — it’s quite possible that Western health care industry interests will be advancing causes that are unlikely to be feasible for most poor countries.

A blue-ribbon bunch of think-tankers called the (somewhat grandiose-sounding) Commission on Smart Global Health Policy recently put out a report — “Smart Global Health” — that does offer some level of prioritization.The group also has a nifty quick video presentation on NCDs.

Cancer and the other NCDs need to be on the global health agenda. But it looks like we’re at the stage of maturation in global health where some triage is also needed – making the tough decisions about what not to do in order to concentrate on where you can help the most.

  • Kristi Heim

    To me these worrying signs amid funding shortfalls point to one giant priority that could save money for both developed and developing countries: prevention

    • http://humanosphere.kplu.org Tom Paulson

      Agreed. The problem, however, is that prevention efforts frequently have no commercial incentives, direct benefits for charitable organizations or even politicians. Many contend that the most effective way to prevent diseases in poor countries, arguably, is to fund basic infrastructure improvements (water, sanitation, education) and also make sure they have an adequate public health system. Put another way, if you had a billion dollars to spend in, say, Tanzania, would it be best to spend it on beefing up cancer care or improving their water/sanitation system? Folks will say “It shouldn’t be an either-or question” but in reality it is ….

      • http://twitter.com/nswa nwscience.org

        Last night, at the Fred Hutch and World Affairs Council event, three caregivers from Oman, the West Bank and Kazakhstan gave wonderful down-and-dirty examples of their low-resource cancer care. But – just like Kristi – they said “prevention” in the form of getting people to identify symptoms earlier – would go a long way. Is that cultural shift so expensive to accomplish?

        • http://humanosphere.kplu.org Tom Paulson

          Two thoughts:

          1. Oman and Kazakhstan are not poor countries lacking basic health services. Both are, in fact, relatively well-off. The West Bank, because of the Israel-Palestine divide, is sort of in its own category. Health services there are restricted not so much because of poverty as because of politics. I assume that ‘global health’ is an enterprise aimed at helping the poorest countries and so the strategies must focus first on their needs.

          2. Early diagnosis by itself doesn’t always prevent cancer. It may simplify treatment for some cancers (not all) but if the community you live in lacks even basic health services, or you are too poor to pay for them, you are still out of luck.

        • Kristi Heim

          Thanks — I was so sorry to have to miss that WAC event. Did anyone tape/blog it?

  • sarah arnquist

     Tom, you raise some excellent points, particularly around prioritization. Whenever I raise similar skepticism that there is sufficient funding, the response I get is “that’s what people said about providing treatment to AIDS patients before 2003 and look what’s happened. Same goes for treating MDR-TB.”

    That being said, there will be a “virtual discussion” happening around financing prevention and treatment for NCDs happening on GHDonline in June following the Global Health Council Conference. Here’s a quick synopsis:

    June 17-24: Funding Challenges for Non-Communicable Diseases in Resource-limited Settings

    Join panelists from the University of Washington, ICAP Columbia, the
    Global Alliance for Clean Cookstoves, ProCor, the Rockefeller
    Foundation, FSG Social Impact Consultants, and the Young Professionals
    Chronic Disease Network to discuss costs, funding, and priority shifting
    questions for non-communicable diseases in resource-limited settings.
    This panel will take place in the Endemic Non-Communicable Diseases community.

  • http://pulse.yahoo.com/_7A55DNLNU3NDDOLJIDWJE5FN7Y Cycledoc

    Cancer care (particularly drug treatments) is unaffordable in industrialized nations. 

    The only approaches that are make sense in less affluent societies education to prevent cancers such as smoking cessation programs,  stopping  international tobacco companies from promoting and selling in third world countries (lung, head and neck cancer and others), interventions to stop the spread of hepatitis B and C (liver cancer), prevention of shistosomiasis (bladder cancer) and perhaps some early diagnosis strategies.

  • Nicolas Andre

    hi ! 
    we need to think of “new” less expensive strategies to fight cancer. It is in our hand to be  creative and unveil adapted solutions !
    Some are already available. For instance, metronomic chemotherapy and drug repositioning allows to propose non expensive, non toxic anticancer treatments.
    It is already happening !
     
    Children treated with metronomic chemotherapy in a low-income country: METROMALI-01. 
    Fousseyni T, Diawara M, Pasquier E, André N.
     J Pediatr Hematol Oncol. 2011 Jan;33(1):31-4.

    Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? Klement GL, Kamen BA.
    J Pediatr Hematol Oncol. 2011 Jan;33(1):1-3.

    We are working on developing this approach ! join in !